IMAC Holdings, Inc. provides services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. Following the discontinuation of patient care operations at all locations as of December 31, 2023, the company acquired certain assets and rights of Theralink Technologies, Inc. in May 2024, including a nationally CLIA-certified, CAP-accredited and New York State Clinical Laboratory Evaluation Program…
IMAC Holdings, Inc. provides services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. Following the discontinuation of patient care operations at all locations as of December 31, 2023, the company acquired certain assets and rights of Theralink Technologies, Inc. in May 2024, including a nationally CLIA-certified, CAP-accredited and New York State Clinical Laboratory Evaluation Program certified laboratory in Golden, Colorado and associated equipment. These assets formed the foundation for Ignite Proteomics LLC, a wholly-owned Delaware subsidiary established on May 30, 2024, to deliver proteomic testing services under licenses from Vanderbilt University and George Mason University.
IMAC Holdings, Inc. generates revenue primarily through clinical diagnostic testing using its Ignite RPPA technology platform, research contracts with academic and biopharmaceutical clients, participation in clinical trials and registries, and strategic partnerships focused on advancing novel targeted therapies. The company offers its Ignite RPPA Assay for Breast Cancer as a commercially available Laboratory Developed Test utilized by oncologists across the United States to assist in treatment planning for patients with advanced breast cancer. It accepts payment from private insurers and is in the process of obtaining credentials for reimbursement by Medicare and other third-party payors for its Ignite proteomics test.
The company operates through the following segments:
- Ignite Proteomics: This segment delivers proteomic testing services using the RPPA technology platform to quantify protein signaling for oncology clinical treatment decisions and biopharmaceutical drug development. It operates under the Ignite brand name, which encompasses the commercialized Ignite RPPA Assay for Breast Cancer and the forthcoming Ignite RPPA Pan-Tumor Assay versions. The segment leverages intellectual property licensed from Vanderbilt University and George Mason University to develop and deliver its diagnostic offerings.
IMAC Holdings, Inc. occupies a specialized position within the oncology diagnostics industry, focusing on proteomic biomarkers that complement standard genomic and proteomic testing to guide cancer therapy selection. Its competitive advantage lies in the patented Reverse Phase Protein Array (RPPA) technology, which identifies activated protein drug targets to predict patient response to specific therapeutics, potentially improving treatment efficacy and reducing healthcare costs. The company differentiates itself through biomarker candidates such as phosphorylated AKT for AKT-targeted drugs, dual-marker HER2/EGFR analysis for neratinib response, and MHC-II for pembrolizumab prediction, which it aims to establish as guideline-recommended via submissions to the National Comprehensive Cancer Network.
IMAC Holdings, Inc. serves oncologists and healthcare providers treating patients with advanced breast cancer and plans to expand to ovarian, endometrial, head and neck, colorectal, prostate, pancreatic, lung, and other solid tumor indications through its evolving Pan-Tumor Assay offerings. The company also engages with biopharmaceutical firms and academic institutions for research collaborations, clinical trial support, and preclinical drug discovery partnerships utilizing its proteomic profiling capabilities.